Association between Asprosin and Clusterin in patients with Myocardial infarction. | ||
| Journal of Bioscience and Applied Research | ||
| Article 29, Volume 11, Issue 3, September 2025, Pages 1046-1054 PDF (980 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/jbaar.2025.385738.1204 | ||
| Authors | ||
| Ahmed Abdulkadhim Hamidy1; Marwah A.K.Hameedi,2; Noor Ali Abdul Jabbar3; Mohammed I hamzah4 | ||
| 1, Chemistry Department, College of Science, Mustansiriyah University , Baghdad – Iraq. | ||
| 2Missions and cultural Relations department, AI-Iraqia University, Baghdad- Iraq. | ||
| 3Biology Department, College of Science, Mustansiriyah University , Baghdad – Iraq. | ||
| 4College of medicine, Alnahrain university, Baghdad – Iraq. | ||
| Abstract | ||
| Background: The most common cause of acute myocardial infarction (AMI) is still plaque rupture. Elevation of ST segments. Myocardial infarction (STEMI) and elevation without ST-segment. There are two forms of AMI, Myocardial Infarction (NSTEMI) and AMI, each with unique clinical features. Asprosin is a newly discovered fasting-induced glucogenic adipokine that stimulates the liver to release glucose into the bloodstream. It has been linked to metabolic disorders like polycystic ovarian syndrome and type II diabetes mellitus. Most biological fluids contain the heterodimeric glycoprotein clusterin, which is produced by a variety of tissues. Based on clusterin's distribution and in vitro properties, several physiological roles have been suggested. A notable and distinctive characteristic of clusterin is its induction in various disease states, including but not limited to glomerulonephritis, polycystic kidney disease, renal tubular injury, and neurodegenerative conditions such as Alzheimer's disease, atherosclerosis, and myocardial infarction. | ||
| Keywords | ||
| Asprosin; clusterin; Lipid Profile; CK-MB; Myocardial infarction | ||
|
Statistics Article View: 105 PDF Download: 32 |
||
